RT Journal Article
SR Electronic
T1 Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.29.21256184
DO 10.1101/2021.04.29.21256184
A1 Marie Tourret
A1 Nana Talvard-Balland
A1 Marion Lambert
A1 Ghada Ben Youssef
A1 Mathieu F. Chevalier
A1 Armelle Bohineust
A1 Thomas Yvorra
A1 Florence Morin
A1 Saba Azarnoush
A1 Olivier Lantz
A1 Jean-Hugues Dalle
A1 Sophie Caillat-Zucman
YR 2021
UL http://medrxiv.org/content/early/2021/04/30/2021.04.29.21256184.abstract
AB Background Mucosal associated invariant T (MAIT) cells are semi-invariant T cells that recognize microbial antigens presented by the highly conserved MR1 molecule. MAIT cells are predominantly localized in the liver and barrier tissues and are potent effectors of anti - microbial defense. MAIT cells are very few at birth and accumulate gradually over a period of about 6 years during infancy. The cytotoxic potential of MAIT cells, as well as their newly described regulatory and tissue repair functions, open the possibility of exploiting their properties in adoptive therapy. A prerequisite for their use as “universal” cells would be a lack of alloreactive potential, which remains to be demonstrated.Methods We used ex vivo, in vitro and in vivo models to determine if human MAIT cells contribute to allogeneic responses.Results We show that recovery of MAIT cells after allogeneic hematopoietic stem cell transplantation recapitulates their slow physiological expansion in early childhood, independent of recovery of conventional T cells. In vitro, signals provided by allogeneic cells and cytokines do not induce sustained MAIT cell proliferation. In vivo, human MAIT cells do not expand nor accumulate in tissues in a model of T-cell mediated xenogeneic graft-versus-host disease (GVHD) in immunodeficient mice.Conclusions Altogether, these results provide evidence that MAIT cells are devoid of alloreactive potential and pave the way for harnessing their translational potential in universal adoptive therapy overcoming barriers of HLA disparity.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02403089Funding StatementThis work was supported by grants from Agence Nationale de la Recherche (ANR) and Direction Generale de l'Offre de Soins (DGOS) (PRTS 14-CE15-0005, acronym NEOMAIT), Agence de la Biomedecine, and Cent pour Sang la vie. N.T-B was supported by Ligue contre le Cancer and Fondation pour la Recherche Medicale (FRM). Access to samples from the CRYOSTEM collection was made possible thanks to the financial support of Association Laurette Fugain.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was carried out with the approval of the Robert Debre Hospital Ethics Committee (HREC 2013/49) and the CPP Ile de France IV (2015/03NICB), in agreement with the principles of the Declaration of Helsinki and French legislation. All subjects (or their parents for the children cohort) provided written informed consent. The study was registered in a public trial registry: ClinicalTrials.gov number NCT0240. Mice were used after approval of all procedures by the Institutional animal Care and Use Ethics Committee (CE121#16624).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/ACFSECarboxyfluorescein succinimidyl esterGVHDgraft-versus-host diseaseGVLgraft-versus-leukemiaHSCThematopoietic stem cell transplantationMAITMucosal associated invariant TMAmyeloablativeNMAnon myeloablativeMSDmatched sibling donorMUDmatched unrelated donorTCRT cell receptorTconvconventional T cells5-OP-RU5-(2-oxopropylideneamino)-6-D-ribitylaminouracil